iRhythm Builds Momentum Following Large Trial Of AI Approach To ECG Analysis
Results from a study of more than 91,000 ECG records collected with iRhythm’s Zio ambulatory continuous cardiac monitoring device that demonstrates the successful application of artificial intelligence to ECGs gives the 12-year-old company confidence that it will be profitable very soon.
You may also be interested in...
Local Medicare carrier Novitas met with monitoring companies to discuss rates for long-term ECG monitoring, but no final decision on recently proposed rate cuts has been reached, iRhythm reported.
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
Who wants to go public during a once-in-a-century crisis? It seems like quite a few medtechs do.